Ascenta Therapeutics (Ascenta)

Oncology Corporate Profile

HQ Location

101 Lindenwood Drive, Suite 405
Malvern, PA 19355

Company Description

Ascenta Therapeutics is a privately-held, clinical stage biopharmaceutical company dedicated to the discovery and development of new medicines to treat cancer. Ascenta's current focus is a portfolio of novel, orally-active, small molecule drugs that restore the natural potential for cancer cells to undergo cell death (apoptosis).

Website: http://www.ascenta.com/index.php

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
AT-101 (+ taxotere)pan-Bcl-2 inhibitor (oral)1st line metastatic hormone-refractory Prostate cancer (HRPC)II
AT-101pan-Bcl-2 inhibitor (oral)1st line metastatic Small Cell Lung Cancer (SCLC)II
AT-101 (+ taxotere)pan-Bcl-2 inhibitor (oral)2nd line metastatic hormone-refractory Prostate cancer (HRPC)II
AT-101 (+ taxotere)pan-Bcl-2 inhibitor (oral)2nd line metastatic Non Small Cell Lung cancer (NSCLC)II
AT-101pan-Bcl-2 inhibitor (oral)2nd line metastatic Small Cell Lung Cancer (SCLC)II
AT-101pan-Bcl-2 inhibitor (oral)Glioblastoma Multiforme (GBM)II
AT-101pan-Bcl-2 inhibitor (oral)Chronic Lymphocytic Leukemia (CLL)I
AT-101pan-Bcl-2 inhibitor (oral)Esophageal cancerI
AT-101pan-Bcl-2 inhibitor (oral)Hormone refractory Prostate cancer (HRPC)I
AT-101pan-Bcl-2 inhibitor (oral)Non-Hodgkin's Lymphoma (NHL)I
AT-406multi-IAP (oral)Various cancer typesI
UnnamedHDM2-p53 inhibitor (oral)Various cancer typesPreclinical

Source: http://www.ascenta.com/index.php

Recent News Headlines

There are no news items to display